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cally smokers demonstrate better prognosis compared with non-
smokers with clopidogrel use. Randomized data have shown
improved outcomes in medically managed smokers treated with
prasugrel rather than clopidogrel for acute coronary syndrome (ACS).
We sought to determine if a similar effect was observed with real
world use for ACS patients undergoing PCI.
METHODS PROMETHEUS was a retrospective multicenter observa-
tional study comparing clopidogrel and prasugrel use in
patients undergoing PCI for acute coronary syndrome. MACE was
deﬁned as a composite of death, myocardial infarction, stroke and
unplanned revascularization at one year. We compared outcomes
between clopidogrel and prasugrel treatment stratiﬁed by smoking
status.
RESULTS Prasugrel was given to 23.5% and 19.3% of smokers
(n¼5006) and non-smokers (n¼14900) respectively. Compared with
clopidogrel, patients receiving prasugrel were younger, male, with
higher BMI and less diabetes or prior PCI. They were more likely to
present with NSTEMI or STEMI and demonstrated higher left ven-
tricular ejection fraction. Although they had a greater incidence of B2/
C lesions, severe calciﬁcation and bifurcation lesions were less com-
mon. The use of bare metal stents was lower in prasugrel treated
patients with a tendency to receive longer stents and stents >2.5mm
in diameter. The overall crude MACE rate for the study population
was 12.1% vs 20.7% with prasugrel compared with clopidogrel,
p<0.001. In the smoking group, prasugrel was associated with a
signiﬁcantly lower risk for MACE prior to adjustment (14.2% vs. 20.7%,
p<0.0001). Analogous event rates in the non-smoking group were
11.2% and 20.6%, respectively (p<0.0001). Results remained signiﬁ-
cant for non-smokers but not smokers with evidence for interaction
after adjustment (p¼0.02) (Figure).
CONCLUSIONS Compared with clopidogrel use, prasugrel was asso-
ciated with an accentuated beneﬁt in non-smokers compared to
smokers with ACS undergoing PCI.CATEGORIES CORONARY: Pharmacology/Pharmacotherapy
KEYWORDS Acute coronary syndromes, Antiplatelet therapy, Smok-
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BACKGROUND The potential beneﬁt of long-term dual antiplatelet
therapy (DAPT) for secondary prevention of atherothrombotic events
in patients with coronary artery disease (CAD) is unclear. Data from
different randomized controlled trials (RCT) using different agents in
different subgroups showed inconsistent results. The goal of this
study was to evaluate the efﬁcacy and safety of long term DAPT for
secondary prevention.METHODS We performed a systematic review and meta-analysis from
RCTs that tested different prolonged durations of DAPT for secondary
prevention. Long term DAPT (L-DAPT) arm was deﬁned as those
receiving DAPT for more than 12 months. The long-term aspirin arm
(L-ASA) was deﬁned as those receiving either long-term aspirin
monotherapy or DAPT for 6 months or less.
RESULTS Our systematic literature search identiﬁed 2456 articles,
of which 6 met the inclusion criteria for this analysis. These 6 RCT
included a total of 47,734 patients (27657 L-DAPT and 20077 L-
ASA). The use of L- DAPT was associated with a signiﬁcant decrease
in composite of death, myocardial infarction (MI) and stroke (6.08%
vs. 6.71%; Odd Ratio OR¼ 0.86 [0.78 -0.94]; P¼0.001). The reduc-
tion was mainly driven by a reduction in MI, but not in death,
cardiac death or stroke. This reduction of death, MI and stroke was
mainly noticed in patients with prior MI (6.32% vs. 7.28%; OR¼
0.86 [0.79 -0.94]; P <0.001) but in those who had PCI with no MI.
The reduction was seen with post PCI patients with prasugrel
(3.10% vs. 5.90%; OR¼ 0.53 [0.37 -0.74]; P<0.001) and only in those
with prior MI with clopidogrel (4.89% vs. 6.28% OR¼ 0.77 [0.66
-0.9]; P<0.01) and ticagrelor (6.95% vs. 5.72%; OR¼ 0.84 [0.75
-0.93]; P¼0.001). Long-term use of DAPT was associated with sig-
niﬁcant increase in major bleeding (1.47% vs. 0.88%; OR¼ 1.65 [1.23
- 2.21]; P¼0.001).
CONCLUSIONS Long-term use of DAPT for secondary prevention is
associated with lower risk of death, MI and stroke in patients with
prior MI, but it is associated with increased risk of bleeding. Pro-
longing DAPT requires careful assessment of the trade-off between
ischemic and bleeding complications and should probably be reserved
for those with highest risk for atherothrombotic events.
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BACKGROUND Previous studies have reported a considerable asso-
ciation hematocrit and hemoglobin had with the VerifyNow P2Y12
assay results. However, little has been documented on association
between results and hematocrit/hemoglobin. This study was con-
ducted to evaluate the inﬂuence of hematocrit/hemoglobin on the
results of 2 different platelet function tests.
METHODS On-treatment platelet reactivity to clopidogrel was
tested in 102 Consecutive patients with AMI or coronary artery
in-stent restenosis treated with standard-dose clopidogrel.
Platelet function was evaluated with both VerifyNow P2Y12 and
VASP assays.
RESULTS Lower hematocrit/hemoglobin was found to be associated
with higher P2Y12 reaction unit (PRU) and a higher rate of HTPR (P
＜0.001) as measured by VerifyNow assay. No differences were seen
among the 4 groups in platelet reactivity measured by VASP assay.
Although the VerifyNow P2Y12 assay results demonstrated a sig-
niﬁcant inverse correlation with hematocrit (r¼0.441, p＜0.005),
there was no such correlation found between the VASP assay re-
sults and hematocrit(r¼0.054, p＞0.05). In multivariate analysis,
anemia was an independent predictor of high on-treatment platelet
reactivity (HTPR), deﬁned as a VerifyNow P2Y12 reaction unit level
of >208 (p＜0.005), but it was found to have no correlation with
VASP assay.
CONCLUSIONS Hematocrit/hemoglobin signiﬁcantly inﬂuenced
the VerifyNow P2Y12 assay results, presumably an in-vitro phe-
nomenon. Lower baseline hematocrit/ hemoglobin was found
to be independently associated with HTPR by VerifyNow P2Y12
assay but not by VASP. Hematocrit level should therefore be
considered when the results of the VerifyNow P2Y12 assay are
interpreted.
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